Head and neck cancer updates at ACSO 2023

1 Views

07/06/23

Ari Rosenberg, MD, Yale School of Medicine, New Haven, CT, summarizes the main take-home messages surrounding head and neck cancers at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress. These include reducing toxicity whilst maintaining, or improving survival outcomes. Trials of interest include those investigating neoadjuvant chemoimmunotherapy, followed by response stratified chemoradiation, and evaluating chemoimmunotherapy and evaluating response, potentially saving patients from any local treatment, such as chemotherapy or surgery. Novel therapies, including those that target EGFR and TGFβ in a bispecific manner, and the use of tissue/blood-based biomarkers to personalize and optimize therapy in head and neck cancer, whilst reducing treatment-linked toxicities, were also discussed. This interview took place at ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.